Table 3.
Summary of immune checkpoint inhibitors used in clinical trials.
| Trial name (ClinicalTrials.gov Identifier) | Treatment | Phase of trial | Number of participants | Primary end point or outcomes | Summary of results |
|---|---|---|---|---|---|
| NCT02017717 | Nivolumab vs. bevacizumab | III | 530 | OS | Median OS 9.5 months vs 9.8 months |
| NCT02617589 | Nivolumab vs. temozolomide in combination with radiation therapy | III | 560 | OS | Median OS 13.4 months vs 14.88 months |
| NCT02667587 | Temozolomide + radiation therapy in combination with nivolumab or placebo | III | 716 | PFS and OS | No survival advantage over placebo |
| NCT04606316 | Nivolumab in combination with ipilimumab and surgery | I | 60 | Tumor infiltrating T lymphocyte density and safety | Ongoing study, estimated completion date 12/2022 |
| NCT03743662 | Nivolumab with radiation therapy and bevacizumab | II | 94 | OS | Ongoing study, estimated completion date 11/2022 |
| NCT02550249 | Neoadjuvant nivolumab | II | 29 | Efficacy and safety | Median OS 7.3 months |
| NCT04396860 | Ipilimumab and nivolumab plus radiation therapy | II/III | 485 | PFS and OS | Ongoing study, estimated completion date 8/2024 |
| NCT02311920 | Ipilimumab and/or nivolumab in combination with temozolomide | I | 32 | DLT | Ongoing study |
| NCT04145115 | Ipilimumab and nivolumab | II | 37 | ORR | Ongoing study, estimated completion date 5/2023 |
| NCT02337491 | Pembrolizumab with or without bevacizumab | II | 80 | MTD, DLT, and PFS | Median OS 8.8 months together vs 10.3 months for pembrolizumab alone |
| NCT02054806 | Pembrolizumab | I | 477 | Best overall response | Median OS 14.4 months |
| NCT02335918 | Combination of varlilumab and nivolumab | I/II | 175 | DLT, ORR, and OS | Study completed, no available info |
| NCT02336165 | Durvalumab monotherapy, with bevacizumab or with radiaotherapy | II | 159 | OS and PFS | Ongoing study |
| NCT03673787 | Atezolizumab in combination with ipatasertib | I/II | 87 | DLT | Ongoing study, estimated completion date 7/2022 |
| NCT03961971 | Anti-Tim-3 in combination with anti-PD-1 and stereotactic radiosurgery | I | 15 | Serious adverse events | Ongoing study, estimated completion date 9/2022 |
| NCT02658981 | Anti-LAG-3 or urelumab alone and in combination with nivolumab | I | 63 | MTD | Ongoing study |
AEs, adverse events; DLT, dose-limiting toxicity; MTD, maximum tolerated dose; OS, overall survival; PFS, progression-free survival; ORR, objective response rate.